Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Coherus BioSciences Stock Price (Quote) NASDAQ:CHRS
$17.00 ( -2.80% ) Friday, 15th Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $15.30 | $18.21 | Friday, 15th Oct 2021 CHRS stock ended at $17.00. This is 2.8% less than the trading day before Thursday, 14th Oct 2021. During the day the stock fluctuated 4.19% from a day low at $16.95 to a day high of $17.66. |
| 90 days | $12.21 | $18.21 | |
| 52 weeks | $12.21 | $22.22 |
Historical Coherus BioSciences prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-15 | $17.63 | $17.66 | $16.95 | $17.00 | 524 306 |
| 2021-10-14 | $17.72 | $17.91 | $17.44 | $17.49 | 329 504 |
| 2021-10-13 | $17.60 | $17.77 | $17.43 | $17.48 | 227 662 |
| 2021-10-12 | $17.75 | $17.75 | $17.23 | $17.52 | 310 370 |
| 2021-10-11 | $17.60 | $18.05 | $17.47 | $17.74 | 470 561 |
| 2021-10-08 | $17.56 | $18.13 | $17.55 | $18.04 | 445 948 |
| 2021-10-07 | $16.66 | $17.61 | $16.64 | $17.60 | 654 824 |
| 2021-10-06 | $16.09 | $16.70 | $15.89 | $16.59 | 551 644 |
| 2021-10-05 | $15.85 | $16.57 | $15.73 | $16.17 | 874 320 |
| 2021-10-04 | $16.53 | $16.75 | $15.75 | $15.81 | 639 217 |
| 2021-10-01 | $16.19 | $16.74 | $15.91 | $16.52 | 1 002 166 |
| 2021-09-30 | $16.29 | $16.68 | $16.02 | $16.07 | 843 196 |
| 2021-09-29 | $16.91 | $17.41 | $16.05 | $16.46 | 982 233 |
| 2021-09-28 | $17.62 | $17.62 | $16.82 | $16.89 | 749 868 |
| 2021-09-27 | $17.92 | $18.21 | $17.76 | $17.79 | 713 497 |
| 2021-09-24 | $17.45 | $17.89 | $17.30 | $17.73 | 426 986 |
| 2021-09-23 | $17.00 | $17.59 | $16.90 | $17.52 | 495 506 |
| 2021-09-22 | $17.30 | $17.44 | $17.03 | $17.06 | 525 277 |
| 2021-09-21 | $17.55 | $17.66 | $17.25 | $17.26 | 598 954 |
| 2021-09-20 | $17.05 | $17.70 | $16.96 | $17.39 | 1 104 404 |
| 2021-09-17 | $16.25 | $17.79 | $16.16 | $17.56 | 3 600 429 |
| 2021-09-16 | $15.68 | $16.04 | $15.30 | $16.03 | 673 204 |
| 2021-09-15 | $16.16 | $16.16 | $15.72 | $15.79 | 482 164 |
| 2021-09-14 | $16.22 | $16.30 | $15.83 | $16.08 | 761 539 |
| 2021-09-13 | $15.38 | $16.24 | $14.98 | $16.17 | 828 888 |
| 2021-09-10 | $15.79 | $15.79 | $15.35 | $15.39 | 399 621 |
| 2021-09-09 | $15.70 | $15.96 | $15.41 | $15.77 | 471 135 |
| 2021-09-08 | $15.15 | $15.64 | $15.05 | $15.64 | 534 011 |
| 2021-09-07 | $15.54 | $15.54 | $14.66 | $15.08 | 891 307 |
| 2021-09-03 | $16.11 | $16.11 | $15.55 | $15.70 | 440 504 |
| 2021-09-02 | $16.08 | $16.28 | $16.01 | $16.23 | 470 025 |
| 2021-09-01 | $15.96 | $16.24 | $15.80 | $16.12 | 412 227 |
| 2021-08-31 | $15.80 | $16.01 | $15.77 | $15.98 | 499 909 |
| 2021-08-30 | $15.84 | $16.04 | $15.78 | $15.84 | 464 892 |
| 2021-08-27 | $15.96 | $16.15 | $15.71 | $15.75 | 928 434 |
| 2021-08-26 | $15.37 | $16.00 | $15.37 | $15.82 | 769 254 |
| 2021-08-25 | $15.37 | $15.59 | $15.05 | $15.45 | 461 485 |
| 2021-08-24 | $15.27 | $15.43 | $14.99 | $15.37 | 471 743 |
| 2021-08-23 | $15.14 | $15.60 | $14.90 | $15.37 | 778 283 |
| 2021-08-20 | $14.23 | $15.29 | $14.20 | $15.00 | 810 141 |
| 2021-08-19 | $14.32 | $15.57 | $14.32 | $14.53 | 2 380 276 |
| 2021-08-18 | $14.68 | $14.68 | $14.13 | $14.14 | 685 217 |
| 2021-08-17 | $14.00 | $14.68 | $13.81 | $14.67 | 802 066 |
| 2021-08-16 | $13.81 | $14.32 | $13.70 | $14.04 | 809 811 |
| 2021-08-13 | $13.59 | $14.11 | $13.41 | $13.93 | 792 818 |
| 2021-08-12 | $13.50 | $13.67 | $13.12 | $13.63 | 396 138 |
| 2021-08-11 | $13.18 | $13.62 | $13.01 | $13.36 | 405 183 |
| 2021-08-10 | $13.14 | $13.50 | $13.02 | $13.20 | 340 880 |
| 2021-08-09 | $12.96 | $13.64 | $12.96 | $13.17 | 472 049 |
| 2021-08-06 | $13.08 | $13.32 | $12.21 | $13.02 | 1 130 892 |
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid ar... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
